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regardless of which drug was initially used (0.62 months av-
erage increase on sorafenib, 95% CI for difference –1.01 to 
2.26, p = 0.43). In second-line treatment, sunitinib showed a 
significantly longer PFS2 than sorafenib (average increase 
2.66 months, 95% CI 1.02–4.3, p = 0.003).  Conclusion: The 
SoSu sequence translates into a longer combined PFS com-
pared to the SuSo sequence. Predominantly the superiority 
of sunitinib regarding PFS2 contributed to the longer com-
bined PFS in sequential use.  Copyright © 2012 S. Karger AG, Basel 
 Introduction 
 Renal cell carcinoma (RCC) is one of the ten most 
common cancers worldwide, being diagnosed predomi-
nantly in more developed countries  [1] . Until the advent 
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 Abstract 
 Objective: To evaluate the optimal sequence for the recep-
tor tyrosine kinase inhibitors (rTKIs) sorafenib and sunitinib 
in metastatic renal cell cancer.  Methods: We performed a 
retrospective analysis of patients who had received sequen-
tial therapy with both rTKIs and integrated these results into 
a pooled analysis of available data from other publications. 
Differences in median progression-free survival (PFS) for 
first- (PFS1) and second-line treatment (PFS2), and for the 
combined PFS (PFS1 plus PFS2) were examined using weight-
ed linear regression.  Results: In the pooled analysis encom-
passing 853 patients, the median combined PFS for first-line 
sunitinib and 2nd-line sorafenib (SuSo) was 12.1 months 
compared with 15.4 months for the reverse sequence (SoSu; 
95% CI for difference 1.45–5.12, p = 0.0013). Regarding first-
line treatment, no significant difference in PFS1 was noted 
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of ‘targeted therapies’, no promising treatment options 
were available for metastatic RCC (mRCC) and the dis-
ease progressed most often rapidly. Receptor tyrosine ki-
nase inhibitors (rTKIs) have significantly altered the clin-
ical course of mRCC. As of today, three rTKIs, namely 
sorafenib, sunitinib and pazopanib, have been approved 
by regulatory authorities and are used routinely  [2–4] . 
Next-generation rTKIs like tivozanib are being evaluated, 
while axitinib is on the brink of entering the clinic. Be-
sides rTKIs, interferon   in combination with the anti-
VEGF antibody bevacizumab and the mTOR inhibitors 
temsirolimus and everolimus are commonly used for 
mRCC therapy  [5–7] . Sunitinib has emerged as the most 
frequently applied drug in first-line therapy, while 
sorafenib has been the first rTKI to be approved for treat-
ment of mRCC after first-line cytokine treatment. After 
introduction of these two drugs into the clinic, control 
rates regarding progression and overall survival (OS) im-
proved markedly  [2, 3] .
 Based on the RECORD-1 trial, second-line therapy 
with everolimus after failure or intolerance to an rTKI is 
a reasonable treatment strategy  [7] . This concept has been 
challenged by several reports evaluating the use of so-
rafenib and sunitinib in a sequential manner  [8–20] . The 
majority of these trials found no evidence for cross-resis-
tance, and thus prolonged exposure to rTKIs by sequen-
tial treatment, at least for a significant subset of patients, 
may be possible. 
 To address this question further, we performed a 
pooled analysis of the available published data as well as 
of our own experience in patients treated at five Swiss 
centers. 
 Patients and Methods 
 The records from patients with mRCC who were treated either 
with sunitinib as first-line treatment and sorafenib as second-line 
treatment (SuSo) or the reverse sequence (SoSu) at five Swiss cen-
ters were retrospectively reviewed and assessed with regard to pro-
gression-free survival (PFS). Data acquisition and analysis was ap-
proved by the local ethics committee (reference ethics committee 
No. KEK-ZH: 2009-0070/0). Response was assessed on imaging 
data available by using the revised Response Evaluation Criteria in 
Solid Tumors (RECIST; version 1.1)  [21] . In patients without avail-
able imaging data, response was assessed by analyzing the radio-
graphic reports or the data entries of the attending physicians in 
the patient charts. PFS1 was defined as time from start of the first 
rTKI to the time of first progression, and PFS2 as time from start 
of the second rTKI to the time of second progression or death by 
any cause. Combined PFS was defined as the sum of PFS1 and PFS2 
for the complete rTKI-sequence efficacy. The treatment-free inter-
val between the sequential rTKI therapies was not included.
 Data for the pooled analysis were collected by searching 
PubMed, Embase and the Cochrane Library. In addition, we 
checked relevant references from seminal articles or reviews for 
studies reported at international meetings. The search term used 
for the PubMed search was: ‘Sorafenib [All Fields] AND Sunitinib 
[All Fields] AND (Sequential [All Fields] OR Renal [All Fields] OR 
(Sequential [All Fields] AND Renal [All Fields])’. The correspond-
ing search term for Embase was: ‘sorafenib’:ab,ti AND 
‘sunitinib’:ab,ti AND [‘sequential’/exp OR ‘renal’/exp OR
(‘sequential’ AND ‘renal’/exp)]’. The cutoff date was May 15, 2011. 
Data regarding basic patient characteristics, treatment sequenc-
ing and PFS for each line of therapy, OS, response and tumor con-
trol rate were registered if available. We integrated all data includ-
ing our own into a pooled analysis and examined differences in 
median PFS using weighted linear regression. The analysis was 
performed with all reported data available and repeated as sensi-
tivity re-analysis after exclusion of the following studies: 
 – studies in which subsets of patients had reportedly received 
anti-angiogenic compounds or chemotherapy before starting 
the sequential TKI treatment.  
 – studies in which the reason for treatment discontinuation was 
not identifiable as PFS. 
 – studies in which treatment discontinuation due to toxicity or 
intolerance was included into the definition of progression.  
 Patients who had received prior cytokine treatment were al-
lowed in the sensitivity re-analysis. This sensitivity re-analysis 
was performed to reduce bias due to heterogeneity of the study 
designs and the patient cohorts. 
 All analysis was performed in the R programming language 
 [22, 23] . 
 Results 
 Twenty-one Swiss patients were identified with suffi-
cient data available regarding combined PFS and added 
to the pooled analysis. The individual treatment deci-
sions regarding the treatment sequence were driven by 
the registration status of the two drugs. Patients were 
initially treated with sorafenib, the first drug registered 
for the use in mRCC, and when Sutent became available 
all subsequent patients were treated with the latter drug. 
The survival data of these patients are summarized in 
 table 1 . After in-depth review of the literature, 19 trials 
have been identified reporting on sequential treatment 
with sunitinib and sorafenib. After exclusion of duplicate 
reports, studies having included other drugs in the se-
quence like mTOR inhibitors and trials with insufficient 
reported data, 12 published studies with sufficient data 
available regarding combined PFS and our own data 
could be included into the pooled analysis ( fig. 1 ). Eleven 
studies were retrospective analyses, and 2 were prospec-
tive trials. Three studies had included patients with
preceding anti-angiogenic or chemotherapy treatment. 
Overall, 853 patients had been treated sequentially and 
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were eligible for analysis (398 patients received SuSo and 
455 patients SoSu), and for 470 (55%) of them, the com-
plete source data were available [247 (62%) patients with 
SuSo and 223 (49%) patients with SoSu]. The details of 
the studies included are depicted in  table  1 . A longer 
combined PFS for the SoSu sequence compared to SuSo 
was found in the pooled analysis (median combined PFS 
on SuSo was 12.1 months compared with 15.4 months on 
SoSu, 95% CI for difference 1.45–5.12, p = 0.0013;  fig. 2 ). 
No statistically significant difference in the time to first 
progression (PFS1) was noted regardless of which drug 
was initially used (median PFS1 was on average 0.62 
months longer on SoSu, 95% CI for difference –1.01 to 
2.26, p = 0.43). In second-line treatment, sunitinib 
showed a significantly longer PFS2 than sorafenib (aver-
age increase of 2.66 months, 95% CI for difference 1.02–
4.3, p = 0.003; ( fig. 3 ).
 These results could also be confirmed by a more ho-
mogenous sensitivity re-analysis after exclusion of 5 
studies (Tamaskar et al. [8] , Sablin et al. [16] , Garcia et al. 
[17] , Dudek et al. [14] and Choueiri et al. [12] ), which ei-
ther reported substantial pre-treatment of the patients 
with anti-angiogenic compounds and chemotherapy, or 
used varying definitions for progression. Of overall 640 
patients with source data available, 470 (73%) were still 
included into this re-analysis. The median combined PFS 
was 12.1 months for SuSo compared with 15.9 months for 
SoSu (95% CI for difference 2.08–5.54, p = 0.0005;  fig. 4 ).
 Neither patient age, gender distribution nor study de-
sign (retrospective vs. prospective) was statistically sig-
nificantly associated with PFS in either line. The impact 
of sequential therapy on OS and treatment-associated 
toxicities could not be assessed due to insufficient data 
reported by the studies.
Table 1.  Trials included with sequential rTKI treatment
Study Design Study 
arms
n
Sequence P atients, n Median PFS, months Median
age
years
Clear-
cell
%
Patients, %
(n = 455) (n = 398) PFS1 PFS2 prior
cytokines
prior chemo-/
anti-angiotherapy
Tamaskar et al. [8] Retro. 2 So]Su
Su]So
4
–
–
5
4.4*
8.6*
7.7*
5.9*
621 931 0
0
25
60
Richter et al. [9] Retro. 2 So]Su
Su]So
5
–
–
5
7.9*
8.5*
9.8*
8.9*
NR
NR
NR
NR
NR
NR
NR
NR
Zimmermann et al. 
[10]
Retro. 1 So]Su 22 – 11.6 5 61.5 100 54.5 0
Choueiri et al. [12] Retro. 2 So]Su
Su]So
31
–
–
7
8.6†
8.1†
5.8†
2.6†
NR
NR
NR
NR
NR
NR
NR
NR
Heuer et al. [13] Retro. 1 So]Su 44 – 9.2 5.7 NR 84 65 0
Dudek et al. [14] Retro. 2 So]Su
Su]So
29
–
–
20
5.1
5.8
13.1
2.8
62
59
86
80
55
80
0
0
Di Lorenzo et al. 
[15]
Prosp. 1 Su]So – 52 5.6 3.7 60 87 21 0
Sablin et al. [16] Retro. 2 So]Su
Su]So
68
–
–
22
6
5.1
6.5
4
60
56
82
86
50
41
18
49
Porta et al. [32] Retro. 2 So]Su
Su]So
90
–
–
99
8.39
7.79
7.89
4.24
58
60
84
87
541 NR
NR
Garcia et al. [17] Prosp. 1 Su]So – 27 13.1 4.4 64 100 37 30
Buchler et al. [18] Retro. 2 So]Su
Su]So
122
–
–
138
7.82
7.23
8.64
5.68
60
61
100
100
94
85
NR
NR
Herrmann et al. 
[19]
Retro. 2 So]Su
Su]So
29
–
–
13
9.3
9.8
3.4
3.8
641 721 0
0
0
0
Own patients
(this study)
Retro. 2 So]Su
Su]So
10
–
–
11
5.39
12.71
6.01
3.71
57.1
57.4
80
73
30
0
0
0
Mea n values are marked with an asterisk, and data reported as treatment duration with a dagger. Retro. = Retrospective; Prosp. = 
prospective; NR = not reported. 1 Reported for the whole patient population.
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n = 27
n = 5
n = 5
n = 13
n = 138
n = 99
n = 17
n = 7
n = 52
n = 22
n = 20
n = 29
n = 5
n = 22
n = 122
n = 11
n = 90
n = 44
n = 31
n = 29
n = 68
n = 4
Garcia*
Richter
Tamaskar
Herrmann
Buchler
Porta
Stenner
Choueiri
Di Lorenzo*
Sablin
Dudek
Dudek
Richter
Zimmermann
Buchler
Stenner
Porta
Heuer
Choueiri
Herrmann
Sablin
Tamaskar
Sunitinib Sorafenib
0 2015105 25
Median PFS (months)
Overall 1,051 reports were screened for eligibility
PubMed: 438, Embase: 601, Cochrane: 12
1,031 reports excluded after review of 
title and/or abstract: mainly reviews, 
case reports, basic science, off topic
12 reports excluded after detailed evaluation:
Duplicate reports (n = 4)
Insufficient data reported (n = 6)
Non-eligible design (n = 2)
Screening of reviews and seminal
 
articles
 identified 2 additional reports
22 reports were assessed in detail
PubMed: 16, Embase: additional 6, Cochrane: 0
12 reports with sufficient data available were
eligible for inclusion into the pooled analysis
 Fig. 1. Flow chart of data acquisition. 
 Fig. 2. Pooled analysis of the median PFS 
from available data in the literature. Com-
bined PFS on SuSo was 12.1 months com-
pared with 15.4 months on SoSu (95% CI 
for difference 1.45–5.12; p = 0.0013). The 
relative proportion of patients from each 
study contributing to the total analysis is 
represented by the varying thickness of the 
bars. Prospective studies are marked with 
an asterisk.  
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 Discussion 
 A longer combined PFS for SoSu compared to SuSo 
was observed in this pooled analysis. The gain in com-
bined PFS was mainly achieved by a prolonged PFS2 with 
sunitinib when given in second line compared to 
sorafenib, with an average increase in median PFS2 of 2.7 
months. While some of the included studies have hinted 
towards a superiority of the SoSu versus the SuSo se-
quence, others have found no difference regarding PFS. 
This discrepancy may be explained by the definition of 
combined PFS by the respective groups. We have ana-
lyzed the PFS period for every treatment line separately 
and calculated the sum of PFS1 and PFS2 without consid-
ering the treatment-free interval. One large study defin-
ing overall PFS from the start of the first rTKI to progres-
12
10
8
6
SuSoa
PF
S1
 (m
on
th
s)
SoSu
12
10
8
6
SuSob
PF
S2
 (m
on
th
s)
4
SoSu
 Fig. 3. Pooled PFS at first- ( a ) and second-
line treatment ( b ) of available trials. Me-
dian PFS1 was on average 0.62 months lon-
ger on sorafenib compared with sunitinib 
(95% CI for difference –1.01 to 2.26, p = 
0.43).  b Sunitinib showed a significantly 
longer PFS than sorafenib regarding me-
dian PFS2 (average increase of 2.66 
months, 95% CI for difference 1.02–4.3,
p = 0.003). 
n = 5
n = 13
n = 138
n = 99
n = 17
n = 52
n = 5
n = 22
n = 122
n = 11
n = 90
n = 44
n = 29
Richter
Herrmann
Buchler
Porta
Stenner
Di Lorenzo*
Richter
Zimmermann
Buchler
Stenner
Porta
Heuer
Herrmann
Sunitinib Sorafenib
0 2015105 25
Median PFS (months)
 Fig. 4. Sensitivity re-analysis of the medi-
an PFS after exclusion of 5 studies. Median 
combined PFS on SuSo was 12.1 months 
compared with 15.9 months on SoSu (95% 
CI for difference 2.08–5.54, p = 0.0005). 
The relative proportion of patients from 
each study contributing to the total analy-
sis is represented by the varying thickness 
of the bars. Prospective studies are marked 
with an asterisk. 
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sion on the second rTKI including the treatment-free in-
terval reported similar efficacy for both treatment 
sequences  [18] . However, when PFS periods are analyzed 
separately without considering the treatment-free inter-
val, sunitinib achieves a prolonged PFS in second-line 
treatment compared with sorafenib (8.64 vs. 5.68 months; 
data from Buchler [hitherto unpubl. results]).
 The impact of the treatment-free interval on total PFS 
may be explained by a more pronounced drug carryover 
effect after cessation of sunitinib compared to sorafenib. 
Another explanation may be that after failure of first-line 
sorafenib patients were earlier willing or fit to receive sec-
ond-line treatment due to less adverse effects of the drug. 
Further, the quality of the progression, slow progression 
versus fast progression, single site versus multiple sites, or 
more or less life-threatening situation, could influence 
the physician’s decision to start second-line therapy. We 
came to the conclusion that the duration of the pause be-
tween therapies cannot be addressed adequately in a 
pooled analysis. Thus, we omitted the interval and com-
pared active treatment times of sequential therapies only. 
OS could not be assessed within our pooled analysis due 
to insufficient data reported in the published studies. 
However, in a recently published analysis of the Swedish 
Health Care registry, median time to death was reported 
to be superior for the SoSu sequence compared to the 
SuSo sequence  [24] . 
 The AXIS study is the first prospective phase III study 
showing a benefit for sequential rTKI therapy. In a sub-
group analysis, axitinib compared favorably to sorafenib 
in second-line treatment after failure of first-line suni-
tinib treatment. The difference was only modest but sta-
tistically significant (4.8 months for axitinib vs. 3.4 
months for sorafenib, p = 0.01). The result highlights the 
fact that after a potent VEGFR TKI the activity of the 
second-line VEGFR rTKI is markedly reduced but still 
active in many patients  [25] .
 Two options based on prospective trial data have now 
been established for patients that have failed first-line 
treatment with sunitinib: changing the mode of action by 
switching to everolimus or maintaining VEGFR inhibi-
tion by using axitinib. The fact that the RECORD-1 study 
had no active control arm and the AXIS study compared 
one rTKI versus another (sorafenib vs. axitinib) allows no 
direct comparison of the two strategies yet. Despite the 
lack of prospective data, several retrospective analyses in-
dicate that both treatment strategies yield nearly equiva-
lent results  [26, 27] . Noteworthy, recent data regarding 
efficacy of further lines of treatment have been published. 
A PFS of 5.5 months for third-line rTKI treatment after 
initial rTKI and second-line everolimus, and a PFS of 4 
months for third-line everolimus after first- and second-
line rTKIs have been reported  [28, 29] . Altogether, the 
most important factor for the outcome of a patient seems 
to be an adequate performance status for receiving se-
quential therapy at all  [26, 30] . 
 The majority of reported studies on rTKI sequencing 
included in this pooled analysis show limited or incom-
plete cross-resistance of sunitinib and sorafenib. This 
makes meaningful responses in second-line therapy 
likely and continuation of rTKI treatment after first-line 
rTKI reasonable. The value of sunitinib as second-line 
treatment has also been suggested by the analysis of the 
final results of the AVOREN trial. Patients treated se-
quentially with bevacizumab and interferon, followed by 
sunitinib, had an unparalleled OS of  1 43 months  [31] . It 
has to be taken into account that patients treated in this 
study appear to be highly selected, as the control group 
receiving placebo had also an extraordinary long median 
OS.
 Our pooled analysis supports sequential treatment of 
sorafenib and sunitinib. The main limitation of this anal-
ysis is its retrospective and heterogeneous nature. Fur-
thermore, there could be case selection and treatment 
bias. Response assessment has been done in some cases 
by interpreting data entries in patient charts rather than 
by imaging analysis, which may have contributed to an 
estimator bias. On the other hand, a pooled analysis of a 
larger patient cohort may overcome drawbacks of small 
studies underpowered to detect significant differences, as 
observed in our own patient collective. In addition, we 
had access to the source data of the two largest reports. 
Thus, the analysis was rather based on patient than on 
summary data. 
 In conclusion, the results presented herein seem to 
confirm that both rTKIs used sequentially result in a lon-
ger PFS compared to single rTKI treatment. They indicate 
that sorafenib and sunitinib do not display relevant cross-
resistance. The therapeutic SoSu sequence translates into 
a longer combined PFS in comparison to SuSo. This 
pooled analysis may help clinicians in choosing a treat-
ment strategy for their patients, but the results from the 
prospective SWITCH trial (ClinicalTrials.gov identifier: 
NCT00732914) have to be awaited before definitive con-
clusions can be drawn on sequential treatment with suni-
tinib and sorafenib.
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